“The OxC-beta pet product is a breakthrough because of its proven results to optimize overall health. It’s like the discovery of a new class of vitamins—it’s unique, affordable and easy, prompting an increase in sales worldwide.”
– Jolyon Burton
President and Head of Investment Banking, Bloom Burton & Co.
News & Media
Avivagen Announces Approval in China, the World’s Largest Commercial Feed Production Market
Ottawa, ON /Business Wire/ May 12, 2022 /– Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing
Avivagen Announces AGM Results and Update to Shareholders Record Year of Progress for OxC-betaTM Adoption Worldwide
Supply agreement with AB Vista in United States, Brazil and Thailand compliments existing partnerships in Asia and Mexico Continued positive
Avivagen Inc. Announces Results for the First Quarter Ending January 31, 2022
Ottawa, ON /Business Wire/ March 30, 2022/ Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and
Avivagen has developed and is commercializing naturally-derived flavoring agents that help optimize feed intake which promotes health in livestock.
Avivagen offers its commercial partners scientifically backed, evidence-based products which are in high demand from multiple channels including veterinarians, farmers and producers, pet owners and retailers.
Avivagen maintains the highest manufacturing standards and is a proud member of the NASC, a self-regulating body, which protects and enhances the integrity of the animal health product industry.
Avivagen is actively collaborating with companies in Canada, the United States, the Philippines, Korea, Vietnam, and Thailand, and we are seeking more relationships internationally.
